GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIFOF) » Definitions » Short-Term Debt

GIFOF (Grifols) Short-Term Debt : $548 Mil (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Grifols Short-Term Debt?

Grifols's Short-Term Debt for the quarter that ended in Dec. 2024 was $548 Mil.

Grifols's quarterly Short-Term Debt declined from Jun. 2024 ($2,765 Mil) to Sep. 2024 ($0 Mil) but then increased from Sep. 2024 ($0 Mil) to Dec. 2024 ($548 Mil).

Grifols's annual Short-Term Debt increased from Dec. 2022 ($613 Mil) to Dec. 2023 ($961 Mil) but then declined from Dec. 2023 ($961 Mil) to Dec. 2024 ($548 Mil).

Grifols Short-Term Debt Historical Data

The historical data trend for Grifols's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Short-Term Debt Chart

Grifols Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 336.90 2,650.41 613.26 960.53 547.78

Grifols Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 960.53 2,765.18 - 547.78

Grifols Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Grifols Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Grifols's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIFOF) » Definitions » Short-Term Debt
Comparable Companies
XMAD:ROVI XMAD:ALM XMAD:FAE XMAD:RJF XMAD:LAB LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE GILD XPAR:SAN BMY TSE:4519 LSE:GSK
Traded in Other Exchanges
GIKLY:USA GIFLF:USA GRFS:USA 1GRF:Italy GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain OZTA:Germany GRF:Austria
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Website
https://www.grifols.com
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.